Abstract: The present invention relates in general to compositions and methods for treating an animal or human patient in need of treatment for ophthalmic diseases or conditions involving oxidative stress and treatment with an ophthalmic implant containing (2R,2R?)-3,3?-disulfanediyl bis(2-cetamidopropanamide) (diNACA), wherein such ophthalmic diseases or conditions include but not limited to cataracts, cataracts in a subject that does not have diabetes, corneal endothelial cell loss, age-related macular degeneration, presbyopia, retinitis pigmentosa (RP), Usher syndrome, Stargardt syndrome, glaucoma, diabetic retinopathy, and/or retinal disease.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: A method of modifying a medical device such as a stent with nano-constructs is disclosed. The method comprises applying a first fluid to the stent; immersing the stent being wet from the first fluid into a second fluid having a suspension of nano-constructs; and removing the stent from the second fluid and allowing the first and second fluid to be removed such that the nano-constructs are carried by the stent for in vivo application of the constructs to a target location of a mammalian subject. The nano-constructs can be attached to the surface of the stent, can be attached to a surface of the coating of the stent, can be embedded into the stent, or can be embedded into the coating.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: A mobile computing device is provided that includes a front housing segment and a back housing segment. The front housing segment includes a first front slot and a first front securement feature or cleat. The back housing segment includes a first back slot and a first securement feature or cleat. The front housing segment and the back housing segment are positioned so that the first back securement feature is received and slideably engaged with the first front slot, and the first front securement feature is received and slideably engaged with the first back cleat. A combination of (i) the first back securement feature being received and slideably engaged with the first front slot, and (ii) the first front securement feature being received and slideably engaged with the first back securement feature, enable the front housing segment and the back housing segment to slide along a path that includes an extended position and a contracted position.

Abstract: A method of modifying a medical device such as a stent with nano-constructs is disclosed. The method comprises applying a first fluid to the stent; immersing the stent being wet from the first fluid into a second fluid having a suspension of nano-constructs; and removing the stent from the second fluid and allowing the first and second fluid to be removed such that the nano-constructs are carried by the stent for in vivo application of the constructs to a target location of a mammalian subject. The nano-constructs can be attached to the surface of the stent, can be attached to a surface of the coating of the stent, can be embedded into the stent, or can be embedded into the coating.

Abstract: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable at a site beneath the skin to reduce, prevent or treat post-operative pain, and the depot is capable of releasing (i) about 5% to about 45% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a first period of up to 48 hours and (ii) about 55% to about 95% of the clonidine or pharmaceutically acceptable salt thereof relative to a total amount of the clonidine or pharmaceutically acceptable salt thereof loaded in the drug depot over a subsequent period of at least 3 days.

Abstract: A mobile computing device is provided that includes a front housing segment and a back housing segment. The front housing segment includes a first front slot and a first front securement feature or cleat. The back housing segment includes a first back slot and a first securement feature or cleat. The front housing segment and the back housing segment are positioned so that the first back securement feature is received and slideably engaged with the first front slot, and the first front securement feature is received and slideably engaged with the first back cleat. A combination of (i) the first back securement feature being received and slideably engaged with the first front slot, and (ii)the first front securement feature being received and slideably engaged with the first back securement feature, enable the front housing segment and the back housing segment to slide along a path that includes an extended position and a contracted position.

Abstract: An earpiece-less lenticular eyeglass frame and removable retainer strap. Attachment mechanisms on each side of the lenticular frame enable a retainer strap to be directly connected to the frame. The retainer strap includes an end-piece at each end of the strap that is compatible with the two attachment mechanisms for attaching the strap to the frame and for removing the strap from the frame. A sliding clasp is used to adjust tension on the retainer strap for different activities such as reading or playing sports. A user may remove the retainer strap to interchange straps or to move the retainer strap from one pair of eyeglasses to another. The absence of earpieces makes the eyeglasses more comfortable, lightweight, less bulky, and less susceptible to damage.

Abstract: An ophthalmic instrument table such as a slit-lamp table having pads attached to a top surface thereof. The pads provide a cushion for a doctor's elbows and/or forearms while the doctor utilizes the ophthalmic instrument to perform an ocular examination. Each pad includes a layer of padding material and an attachment mechanism for attaching the pad to the table. The pad may also include a firm substrate panel for supporting the layer of padding material, and a covering material for covering the padding material and the substrate panel. The pad may be shaped to conform to the side and front of the table, and to an ophthalmic instrument mounted on the table. The attachment mechanism enables a user to remove the pad from the table, use the pad on another table, or reposition the pad on the table by lifting the pad by hand.

Abstract: The present invention is directed to systems and methods for providing a software developer's toolbox for generating and deploying a software application. While several preferred embodiments are directed toward a modular toolbox for generating and deploying web-based enterprise applications deployable onto J2EE-compliant servers, all embodiments are not so limited and can be directed toward the generation and deployment of software applications that are compatible with non-Internet networks such as private networks, local networks, and intranets and further are compatible with non-networked applications including Windows and non-Windows operating system applications. Further, exemplary embodiments can provide for the generation and deployment of software applications written in non-Java code.

Abstract: A die-level test and burn-in flipping tray. A tray having a plurality of pockets adapted to receive die-level carriers formed thereon is provided. The pockets are defined by four risers, one riser defining each corner of the pocket and a support at the base of each riser to support a die-level carrier disposed within the pocket. The riser and the tray are molded such that a second tray may be mated with the original tray, the second tray having pockets in one-to-one correspondence with the first tray. The mated tray pair may then be inverted causing carriers in pockets of the first tray to transition under the influence of gravity to corresponding pockets of the second tray in an orientation inverted about the z-axis.

Abstract: A die-level test and burn-in flipping tray. A tray having a plurality of pockets adapted to receive die-level carriers formed thereon is provided. The pockets are defined by four risers, one riser defining each corner of the pocket and a support at the base of each riser to support a die-level carrier disposed within the pocket. The riser and the tray are molded such that a second tray may be mated with the original tray, the second tray having pockets in one-to-one correspondence with the first tray. The mated tray pair may then be inverted causing carriers in pockets of the first tray to transition under the influence of gravity to corresponding pockets of the second tray in an orientation inverted about the z-axis.